BUSINESSNDTV Profit ยท 2 hours agoLive
AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Late-Stage Trial
Reported by NDTV Profit, not nibnow. We are not the publisher of this story, only the source is.
FROM THE SOURCE
Astra has pegged potential annual sales for the treatment, whose full name is sonesitatug vedotin, at between $3 billion and $5 billion. It targets a protein found in the lining of the stomach that's expressed in some gastric cancers.